Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis.

Abstract

Pure serum amyloid P component (SAP) was isolated from a normal donor pool, from individuals with the different genotypes of an MspI restriction fragment length polymorphism (RFLP) linked to the SAP gene, and from a patient with AA amyloidosis. The SAP preparations were all identical and all behaved as a single homogeneous species in polyacrylamide gel electrophoresis, isoelectric focussing, reverse-phase chromatography, binding in vitro to phosphoethanolamine-Sepharose (binding constant 2.4 x 10(7) l/mol) and AL amyloid fibrils (1.6 x 10(8) l/mol), and binding to amyloid deposits in vivo in mice with casein-induced amyloidosis. The in vivo metabolism of 125I-SAP from a single donor was normal and identical in three healthy individuals representing the three different MspI RFLP genotypes. There is thus no frequent polymorphism of SAP in normal subjects, and SAP altered with respect to the characteristics studied here is not a necessary condition for pathogenesis of systemic AA amyloidosis.

• Authors: P N Hawkins, G A Tennent, P Woo, M B Pepys
• Journal: Clinical and experimental immunology (Clin Exp Immunol) Vol. 84 Issue 2 Pg. 308-16 (May 1991) ISSN: 0009-9104 [Print] England
• PMID: 1673879 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Serum Amyloid P-Component
• Calcium

Topics

• Amyloidosis (metabolism)
• Binding, Competitive (drug effects)
• Calcium (pharmacology)
• Electrophoresis, Polyacrylamide Gel
• Humans
• Isoelectric Focusing
• Kidney (metabolism)
• Liver (metabolism)
• Polymorphism, Genetic
• Polymorphism, Restriction Fragment Length
• Serum Amyloid P-Component (analysis, isolation & purification, pharmacokinetics)
• Spleen (metabolism)